KR20220106862A - 허혈에 대한 psd-95 억제제와의 조합 요법 - Google Patents

허혈에 대한 psd-95 억제제와의 조합 요법 Download PDF

Info

Publication number
KR20220106862A
KR20220106862A KR1020227025470A KR20227025470A KR20220106862A KR 20220106862 A KR20220106862 A KR 20220106862A KR 1020227025470 A KR1020227025470 A KR 1020227025470A KR 20227025470 A KR20227025470 A KR 20227025470A KR 20220106862 A KR20220106862 A KR 20220106862A
Authority
KR
South Korea
Prior art keywords
ischemia
subject
psd
reperfusion therapy
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227025470A
Other languages
English (en)
Korean (ko)
Inventor
마이클 타이미안스키
Original Assignee
노노 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노노 인코포레이티드 filed Critical 노노 인코포레이티드
Publication of KR20220106862A publication Critical patent/KR20220106862A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Dermatology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
KR1020227025470A 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법 Pending KR20220106862A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161501117P 2011-06-24 2011-06-24
US61/501,117 2011-06-24
US201261617001P 2012-03-28 2012-03-28
US61/617,001 2012-03-28
KR1020217026955A KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
PCT/IB2012/053178 WO2012176172A2 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026955A Division KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Publications (1)

Publication Number Publication Date
KR20220106862A true KR20220106862A (ko) 2022-07-29

Family

ID=47423033

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020227025470A Pending KR20220106862A (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020147001639A Expired - Fee Related KR102022116B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020217026955A Active KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020197026571A Expired - Fee Related KR102140169B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020207021829A Expired - Fee Related KR102296106B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020147001639A Expired - Fee Related KR102022116B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020217026955A Active KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020197026571A Expired - Fee Related KR102140169B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020207021829A Expired - Fee Related KR102296106B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Country Status (19)

Country Link
US (3) US10064910B2 (https=)
EP (3) EP4052721A1 (https=)
JP (5) JP6401057B2 (https=)
KR (5) KR20220106862A (https=)
CN (1) CN103648518B (https=)
AU (1) AU2012274910B2 (https=)
CA (1) CA2839630A1 (https=)
CY (1) CY1121379T1 (https=)
DK (2) DK2723363T3 (https=)
ES (2) ES2912042T3 (https=)
HR (2) HRP20220519T1 (https=)
HU (2) HUE040564T2 (https=)
LT (1) LT2723363T (https=)
PL (2) PL2723363T3 (https=)
PT (2) PT3427748T (https=)
RS (1) RS57798B1 (https=)
SI (1) SI2723363T1 (https=)
SM (1) SMT201800592T1 (https=)
WO (1) WO2012176172A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
ES2912042T3 (es) 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CZ2012476A3 (cs) * 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
WO2015080859A1 (en) * 2013-11-26 2015-06-04 Trustees Of Dartmouth College Method for mitigating or alleviating synaptic and cognitive deficits
FR3021319B1 (fr) * 2014-05-22 2018-08-31 Sederma Peptides, compositions les comprenant et utilisations notamment cosmetiques
CZ309217B6 (cs) * 2014-05-27 2022-06-01 Ústav Organické Chemie A Biochemie Av Čr, V.V.I. Lipidované peptidy jako neuroprotektiva
WO2015181756A1 (en) 2014-05-28 2015-12-03 Nono Inc. Chloride salt of tat-nr2b9c
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
CN104497106B (zh) * 2014-12-05 2017-05-10 华中科技大学 一种小分子多肽、其应用及产品
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
EP3450446A1 (en) * 2016-04-27 2019-03-06 Biocells (Beijing) Biotech Co., Ltd. Treatment method for excitatory neurotoxicity-related injury
CN107446016A (zh) * 2016-05-30 2017-12-08 上海交通大学 一种硬脂酸修饰的细胞穿膜肽及其制备与应用
CN106265594B (zh) * 2016-09-21 2019-07-26 南京医科大学 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法
CN106749559B (zh) * 2016-11-23 2020-09-04 郑州大学 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法
JP7109958B2 (ja) * 2017-04-04 2022-08-01 キヤノンメディカルシステムズ株式会社 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法
WO2019006691A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防脑出血的肽及其用途
KR102403089B1 (ko) 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
KR102545825B1 (ko) * 2017-09-30 2023-06-22 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
US12122811B2 (en) 2018-04-06 2024-10-22 Northwestern University BDNF mimetic peptide amphiphiles
JP7158904B2 (ja) * 2018-06-14 2022-10-24 社会福祉法人 恩賜財団済生会熊本病院 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
US20230055441A1 (en) * 2020-01-09 2023-02-23 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
US20230285504A1 (en) * 2020-02-19 2023-09-14 Nono Inc. Inhibition of reperfusion injury with a psd-95 inhibitor
WO2021165888A1 (en) * 2020-02-19 2021-08-26 Nono Inc. Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
US20250205317A1 (en) * 2022-03-28 2025-06-26 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
KR20250134625A (ko) 2023-01-09 2025-09-11 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 신경 보호적 psd-95 폴리펩티드 억제제 및 이의 응용
CN117422722B (zh) * 2023-12-19 2024-03-29 北京智源人工智能研究院 基于adc图像的肿瘤预后特征评估的方法和装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742152B1 (fr) 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
CA2523565A1 (en) 2003-04-25 2004-11-11 Mitos Incorporated Prophylactic pretreatment with antioxidants
CA2524573A1 (en) * 2003-05-02 2004-11-11 Paion Deutschland Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
BRPI0410470A (pt) * 2003-05-19 2006-06-20 Kenneth S Warren Inst Inc uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
DK2043671T3 (da) * 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
GB0707348D0 (en) 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
EP2205623B1 (en) 2007-10-29 2016-03-16 Helix Biomedix Inc. Protective skin care tetrapeptides
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
AU2009207645B2 (en) 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CA2665302A1 (en) 2009-05-01 2010-11-01 Universite De Montreal Cd36 modulation and uses thereof
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
US20110144029A1 (en) 2009-09-30 2011-06-16 Board Of Regents, The University Of Texas System Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
ES2912042T3 (es) * 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
MX364562B (es) 2011-12-13 2019-04-30 Nono Inc Terapia para hemorragia subaracnoidea e isquemia.

Also Published As

Publication number Publication date
US20190091283A1 (en) 2019-03-28
EP3427748A1 (en) 2019-01-16
WO2012176172A2 (en) 2012-12-27
JP2020189859A (ja) 2020-11-26
US20210308209A1 (en) 2021-10-07
JP6401057B2 (ja) 2018-10-03
KR20190107195A (ko) 2019-09-18
KR102425466B1 (ko) 2022-07-25
JP7085457B2 (ja) 2022-06-16
EP4052721A1 (en) 2022-09-07
PT2723363T (pt) 2018-11-08
US10967041B2 (en) 2021-04-06
JP2014520142A (ja) 2014-08-21
KR102140169B1 (ko) 2020-07-31
US11878044B2 (en) 2024-01-23
ES2690994T3 (es) 2018-11-23
SI2723363T1 (sl) 2018-12-31
KR20140053971A (ko) 2014-05-08
AU2012274910A1 (en) 2014-01-16
KR102296106B1 (ko) 2021-08-30
PL3427748T3 (pl) 2022-05-30
US20140248257A1 (en) 2014-09-04
HRP20181526T1 (hr) 2018-12-14
AU2012274910B2 (en) 2017-05-11
EP2723363A4 (en) 2014-12-10
WO2012176172A3 (en) 2013-03-28
KR20210109661A (ko) 2021-09-06
PT3427748T (pt) 2022-05-03
JP2022188068A (ja) 2022-12-20
JP2017193535A (ja) 2017-10-26
RS57798B1 (sr) 2018-12-31
EP2723363A2 (en) 2014-04-30
DK3427748T3 (da) 2022-04-19
PL2723363T3 (pl) 2018-12-31
US10064910B2 (en) 2018-09-04
CA2839630A1 (en) 2012-12-27
HUE058238T2 (hu) 2022-07-28
LT2723363T (lt) 2018-10-25
KR20200092437A (ko) 2020-08-03
EP3427748B1 (en) 2022-03-02
ES2912042T3 (es) 2022-05-24
JP7143374B2 (ja) 2022-09-28
HUE040564T2 (hu) 2019-03-28
DK2723363T3 (en) 2018-10-15
CN103648518A (zh) 2014-03-19
KR102022116B1 (ko) 2019-09-18
JP2019038831A (ja) 2019-03-14
CY1121379T1 (el) 2020-05-29
SMT201800592T1 (it) 2019-01-11
EP2723363B1 (en) 2018-08-29
HRP20220519T1 (hr) 2022-05-27
CN103648518B (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
KR102425466B1 (ko) 허혈에 대한 psd-95 억제제와의 조합 요법
US11338015B2 (en) Therapy for subarachnoid hemorrhage and ischemia
KR102114490B1 (ko) 지주막하 출혈 및 허혈에 대한 치료법
HK40003366B (en) Combination therapy for ischemia
HK40003366A (en) Combination therapy for ischemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220721

Application number text: 1020217026955

Filing date: 20210824

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230321

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231026

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240709